patients

MannKind If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under…

The new NICE threshold will rise to £25,000 to £35,000 for every quality adjusted life year. In return…

This week in African health news: Global measles cases have dropped nearly 80 percent since 2000, but major…

Around 20,000 visitors are expected at the three-day event. — © AFP Why are more cannabis users landing…

Luca Goodwin, 11, was born with a congenital heart defect and had to undergo three rounds of open-heart…

Christy Houvouras exercises daily, eats right and has smoked fewer than 20 cigarettes in her lifetime. That’s why…

New research coordinated by the Ottawa Heart Institute is being called a game-changer for people with atrial fibrillation…

Dozens of patients were put at risk after two of the UK’s leading transplant centres continued fitting a…

BioXcel Therapeutics sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based…

The U.S. health care reimbursement system was built for a different era — one that prioritized high-stakes “cure”…

Christy Houvouras exercises daily, eats right and has smoked fewer than 20 cigarettes in her lifetime. That’s why…

One-in-10 mental health patients in South Australian hospital emergency departments are waiting “more than 35 hours” for a…

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease